Log in
Enquire now
‌

US Patent 6838290 Methods for screening compounds that affect IL-1 epsilon activity

Patent 6838290 was granted and assigned to Immunex on January, 2005 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
0
Current Assignee
Immunex
Immunex
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
68382900
Patent Inventor Names
Dirk E. Smith0
John E. Sims0
Date of Patent
January 4, 2005
0
Patent Application Number
099700330
Date Filed
October 2, 2001
0
Patent Citations Received
‌
US Patent 11884719 Anti-IL-36 antibodies and methods of use thereof
0
Patent Primary Examiner
‌
Janet Andres
0
Patent abstract

The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, the use of such polypeptides in cellular and immune reactions, the use of such polypeptides in screening for agonists or antagonists of IL-1 epsilon activity, and kits comprising such polypeptides.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 6838290 Methods for screening compounds that affect IL-1 epsilon activity

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.